Clinical TrialsThe Phase 3 SELVA trial has exceeded the enrollment target of 40 patients, demonstrating a strong interest in the program by the community.
Financial OutlookThe company has $75.6M cash which provides runway through the second half of 2027, covering multiple trials and product developments.
Market PotentialMicrocystic lymphatic malformations represent a huge unmet need in the medical field, as there are no approved therapies yet, making QTORIN a potentially valuable treatment option.